Abstract

We aimed to quantitatively and qualitatively assess whether there is a discrepancy in detecting amyloid beta (Aβ) positivity between 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) positron emission tomography (PET). We obtained paired FBB and FMM PET images from 107 participants. Three experts visually quantified the Aβ deposition as positive or negative. Quantitative assessment was performed using global cortical standardized uptake value ratio (SUVR) with the whole cerebellum as the reference region. Inter-rater agreement was excellent for FBB and FMM. The concordance rates between FBB and FMM were 94.4% (101/107) for visual assessment and 98.1% (105/107) for SUVR cut-off categorization. Both FBB and FMM showed high agreement rates between visual assessment and SUVR positive or negative categorization (93.5% in FBB and 91.2% in FMM). When the two ligands were compared based on SUVR cut-off categorization as standard of truth, although not statistically significant, the false-positive rate was higher in FMM (9.1%) than in FBB (1.8%) (p = 0.13). Our findings suggested that both FBB and FMM had excellent agreement when used to quantitatively and qualitatively evaluate Aβ deposits, thus, combining amyloid PET data associated with the use of different ligands from multi-centers is feasible.

Highlights

  • Amyloid positron emission tomography (PET) is a widely used biomarker-supported method for diagnosing Alzheimer’s disease (AD)[1]

  • To determine amyloid beta (Aβ) peptide deposition positivity, visual assessment is generally performed by an expert and quantitative assessment is used for research p­ urposes[2]

  • In terms of visual assessment and standardized uptake value ratio (SUVR) cut-off categorization, the concordance rate for Aβ positivity between FBB and FMM was investigated in 107 participants who underwent both FBB and FMM PET for Aβ deposits

Read more

Summary

Introduction

Amyloid positron emission tomography (PET) is a widely used biomarker-supported method for diagnosing Alzheimer’s disease (AD)[1]. A quantitative method for assessing amyloid deposition uses the cortical-to-reference region standardized uptake value ratio (SUVR). Scanning protocols are relatively similar across the tracers, FDA-approved visual rating guidelines to determine a scan positive or negative differ considerably. These differences include color scale used, intensity scaling, region definitions, as well as spatial and signal thresholds to determine positivity. The discrepancy in detecting amyloid positivity between FBB and FMM PET was investigated using visual assessment, SUVR and direct comparison of FBB-FMM Centiloid (dcCL) cut-off categorization. The discrepancy rate between visual assessment and SUVR cut-off categorization in FBB and FMM was examined.

Objectives
Methods
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call